Tue, October 4, 2011
Mon, October 3, 2011
[ Mon, Oct 03rd 2011 ] - Market Wire
Medwell Capital to Adopt IFRS
Sun, October 2, 2011
Sat, October 1, 2011
Fri, September 30, 2011
Thu, September 29, 2011
Wed, September 28, 2011
Tue, September 27, 2011
Mon, September 26, 2011
Sat, September 24, 2011
Fri, September 23, 2011
Thu, September 22, 2011
Wed, September 21, 2011
Tue, September 20, 2011
Mon, September 19, 2011
Sun, September 18, 2011
Sat, September 17, 2011
Fri, September 16, 2011
Thu, September 15, 2011
Wed, September 14, 2011
Tue, September 13, 2011
Mon, September 12, 2011
Sun, September 11, 2011
Sat, September 10, 2011
Fri, September 9, 2011
Thu, September 8, 2011
Wed, September 7, 2011

Ironwood Pharmaceuticals to Present at Jefferies 2011 Global Healthcare Conference


//health-fitness.news-articles.net/content/2011/ .. jefferies-2011-global-healthcare-conference.html
Published in Health and Fitness on Wednesday, September 21st 2011 at 12:02 GMT by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--[ Ironwood Pharmaceuticals, Inc. ] (NASDAQ: IRWD) will present at the Jefferies 2011 Global Healthcare Conference in London on Wednesday, September 28, 2011, at 9:20 a.m. British Summer Time / 4:20 a.m. Eastern Daylight Time.

A live webcast of Ironwooda™s presentation will be accessible through the Investors section of the companya™s website at [ www.ironwoodpharma.com ]. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwooda™s website for 14 days following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwooda™s GC-C agonist, is an investigational drug for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. The efficacy portion of linaclotidea™s development program has been completed and supports the recently submitted NDA for both indications, as well as the anticipated MAA submission for the IBS-C indication. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass. To learn more, visit [ www.ironwoodpharma.com ].


Publication Contributing Sources